243 related articles for article (PubMed ID: 23629633)
21. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
Nagayama A; Hayashida T; Jinno H; Takahashi M; Seki T; Matsumoto A; Murata T; Ashrafian H; Athanasiou T; Okabayashi K; Kitagawa Y
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25224562
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
23. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
25. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
[TBL] [Abstract][Full Text] [Related]
26. Trastuzumab containing regimens for early breast cancer.
Moja L; Tagliabue L; Balduzzi S; Parmelli E; Pistotti V; Guarneri V; D'Amico R
Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD006243. PubMed ID: 22513938
[TBL] [Abstract][Full Text] [Related]
27. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
[TBL] [Abstract][Full Text] [Related]
28. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
30. Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer.
Morris PG; Iyengar NM; Patil S; Chen C; Abbruzzi A; Lehman R; Steingart R; Oeffinger KC; Lin N; Moy B; Come SE; Winer EP; Norton L; Hudis CA; Dang CT
Cancer; 2013 Nov; 119(22):3943-51. PubMed ID: 24037735
[TBL] [Abstract][Full Text] [Related]
31. Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis.
Long HD; Lin YE; Zhang JJ; Zhong WZ; Zheng RN
Oncologist; 2016 May; 21(5):547-54. PubMed ID: 27026675
[TBL] [Abstract][Full Text] [Related]
32. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
33. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
Sabatier R; Gonçalves A
Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
[TBL] [Abstract][Full Text] [Related]
34. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
Ewer MS; O'Shaughnessy JA
Clin Breast Cancer; 2007 Jun; 7(8):600-7. PubMed ID: 17592672
[TBL] [Abstract][Full Text] [Related]
35. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Blumenthal GM; Scher NS; Cortazar P; Chattopadhyay S; Tang S; Song P; Liu Q; Ringgold K; Pilaro AM; Tilley A; King KE; Graham L; Rellahan BL; Weinberg WC; Chi B; Thomas C; Hughes P; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2013 Sep; 19(18):4911-6. PubMed ID: 23801166
[TBL] [Abstract][Full Text] [Related]
36. Cardiac toxicity of ErbB2-targeted therapies: what do we know?
Perez EA
Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S114-20. PubMed ID: 18777950
[TBL] [Abstract][Full Text] [Related]
37. Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis of randomized controlled trials.
Xin Y; Guo WW; Huang Q; Zhang P; Zhang LZ; Jiang G; Tian Y
Cancer Med; 2016 Dec; 5(12):3454-3463. PubMed ID: 27882700
[TBL] [Abstract][Full Text] [Related]
38. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
39. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
Venturini M; Bighin C; Monfardini S; Cappuzzo F; Olmeo N; Durando A; Puglisi F; Nicoletto O; Lambiase A; Del Mastro L
Breast Cancer Res Treat; 2006 Jan; 95(1):45-53. PubMed ID: 16267615
[TBL] [Abstract][Full Text] [Related]
40. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
